Results 151 to 160 of about 16,733 (229)

The in vitro activity of aztreonam-avibactam and cefiderocol against globally collected clinical metallo-β-lactamase- and/or serine-carbapenemase-positive Enterobacterales isolates and the utility of commonly used in vitro diagnostic kits

open access: yesMicrobiology Spectrum
The NG-test CARBA 5 and Xpert Carba-R IVD kits were tested against 269 clinical Enterobacterales isolates selected for their previously determined carbapenemase content from the ATLAS Global Surveillance program, primarily from 2020 to 2022 ...
Mark Estabrook   +5 more
doaj   +1 more source

Characterization of Enterobacter cloacae and Citrobacter freundii Species Complex Isolates with Decreased Susceptibility to Cephalosporins from United States Hospitals and Activity of Aztreonam–Avibactam and Comparator Agents (2019–2023)

open access: yesAntibiotics
Background: Citrobacter freundii (CFC) and Enterobacter cloacae (ECLC) species complexes represent important causes of hospital-associated infections, frequently are related to outbreaks, and have a great ability to develop antimicrobial resistance.
H. Sader   +4 more
semanticscholar   +1 more source

Antibiotics for the Treatment of Patients with Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacterial Infections

open access: yesAntibiotics
Infections caused by MBL-producing Gram-negative bacterial pathogens have disseminated worldwide and are associated with considerable morbidity and mortality.
Matthew E. Falagas   +3 more
doaj   +1 more source

Successful dual therapy of aztreonam and ceftazidime–avibactam for multidrug-resistant infection in a preterm neonate: A life-saving approach

open access: yesJournal of International Medical Research
Stenotrophomonas maltophilia is a multidrug-resistant gram-negative pathogen associated with high morbidity and mortality, especially in immunocompromised patients.
Abdulrahman O Alghamdi   +9 more
doaj   +1 more source

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics

open access: yesPathogens
The growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics.
Maria Sargianou   +4 more
doaj   +1 more source

Publication Only

open access: yes
HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source

Microb Drug Resist [PDF]

open access: yes
Current antimicrobial treatment recommendations for melioidosis, the disease caused by |, are largely based on studies of strains isolated from the Eastern Hemisphere (EH), where most human cases are identified and reported.

core  

Emerg Infect Dis [PDF]

open access: yes
cdc:109710Correction: Vol. 27, No. 9The acknowledgments and funding information were inaccurate in Severe Acute Respiratory Syndrome Coronavirus 2 in Farmed Mink (Neovison vison), Poland (L. Rabalski et al.). The article has been corrected on-line (https:

core  

Semi-mechanistic pharmacokinetic/pharmacodynamics modeling of aztreonam-avibactam combination against multidrug resistant Gram(-) organisms

open access: yes, 2018
Background: Aztreonam-avibactam (ATM-AVI) is a promising combination to treat serious infections caused by multi-drug resistant (MDR) pathogens including those producing metallo-β-lactamases (MBLs). The aim of this study was to apply a semi-mechanistic PK/PD modelling approach (Sy et al., CPT Pharmacometrics Syst.
Chauzy, Alexia   +8 more
openaire   +1 more source

Home - About - Disclaimer - Privacy